Inflexor Ventures

Our partners, Venkat Vallabhaneni , Jatin Desai , Pratip Mazumdar , Murali Krishna Gunturu and Harsha Mundhada , kicking off our Annual General Meeting (AGM), IGNITE 2025. 💰🚀🇮🇳

We’re excited to share that Inflexor has participated in Atomberg Technologies’ Series C extension round, where the company raised USD 24 million (₹212 crore) led by Temasek. This marks another strong milestone in their journey of building energy-efficient, category-leading appliances. Read the full coverage: https://lnkd.in/gT_esdXy #atomberg #funding #vc

We’re excited to share that Inflexor has participated in Atomberg Technologies’ Series C extension round, where the company raised USD 24 million (₹212 crore) led by Temasek. This marks another strong milestone in their journey of building energy-efficient, category-leading appliances. Read the full coverage: https://lnkd.in/gT_esdXy #atomberg #funding #vc

Understanding the full spectrum of go-public pathways is essential for founders building long-term, resilient companies. From traditional IPOs to direct listings, SPAC mergers, reverse takeovers, and strategic M&A- each route carries distinct implications for capital, valuation, and growth. A clear view of these options empowers founders to plan confidently and align their exit strategy with evolving market conditions. Swipe to read. #startups #exits #public #ipo #funds #venturecapital #midweektip

Inflexor Ventures' Partner Murali Krishna Gunturu is featured in GoodReturns’ latest story on how fintechs are addressing India’s SME credit gap. He highlights how CredFlow - an Inflexor portfolio company -is leveraging real-time accounting and cash-flow data to strengthen underwriting, enable faster decisions, and make small-ticket SME lending more sustainable. With supportive policy tailwinds and rising credit demand, data-driven SME lending is emerging as a high-growth opportunity for the years ahead. P.S.- Thank you, Vipul Das, and GoodReturns, for the insightful feature 🌟 🔗 Read the full story: https://lnkd.in/gHBYaKw7

🚀 𝗜𝗻𝗳𝗹𝗲𝘅𝗼𝗿 𝗩𝗲𝗻𝘁𝘂𝗿𝗲𝘀 𝘅 𝗠𝗼𝗿𝗽𝗵𝗹𝗲 𝗟𝗮𝗯𝘀 | 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 At Inflexor Ventures, we believe that some of the most transformative companies are built by founders who choose to solve the quiet, under-addressed problems, the ones hiding in plain sight, yet fundamental to global health and human outcomes. Our latest investment in Morphle Labs Inc., as they raise $𝟱𝗠 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔, is exactly that kind of story 🌍✨ For decades, histopathology, the core of cancer diagnostics, has remained one of the least automated parts of healthcare. While radiology and genomics have leapt ahead with digital adoption, labs worldwide still depend on manual, painstaking processes that slow down diagnosis, limit scale, and constrain specialists. Morphle is changing this, not with marginal improvements, but with a first-principles rebuild of how tissue diagnostics should work. Their flagship innovations- 🔹 𝗥𝗼𝗯𝗼𝗧𝗼𝗺𝗲®️, the world’s first high-throughput robotic microtome, and 🔹 𝗠𝗼𝗿𝗽𝗵𝗼𝗟𝗲𝗻𝘀, a next-gen AI-driven slide scanner — Together, create a fully automated pipeline that dramatically improves speed, consistency, and clinical readiness. With 80+ patents, a deeply technical founding team, and strong early traction across the U.S. and Europe, Morphle represents the kind of physical-AI innovation India is now capable of building for the world 🇮🇳➡️🌏 As our Partner Pratip Mazumdar shared during the announcement: “𝙈𝙤𝙧𝙥𝙝𝙡𝙚 𝙇𝙖𝙗𝙨 𝙞𝙨 𝙩𝙧𝙖𝙣𝙨𝙛𝙤𝙧𝙢𝙞𝙣𝙜 𝙤𝙣𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙢𝙤𝙨𝙩 𝙤𝙫𝙚𝙧𝙡𝙤𝙤𝙠𝙚𝙙 𝙮𝙚𝙩 𝙢𝙞𝙨𝙨𝙞𝙤𝙣-𝙘𝙧𝙞𝙩𝙞𝙘𝙖𝙡 𝙨𝙚𝙜𝙢𝙚𝙣𝙩𝙨 𝙤𝙛 𝙜𝙡𝙤𝙗𝙖𝙡 𝙝𝙚𝙖𝙡𝙩𝙝𝙘𝙖𝙧𝙚. 𝙏𝙝𝙚𝙞𝙧 𝙖𝙗𝙞𝙡𝙞𝙩𝙮 𝙩𝙤 𝙗𝙧𝙞𝙣𝙜 𝙩𝙤𝙜𝙚𝙩𝙝𝙚𝙧 𝙧𝙤𝙗𝙤𝙩𝙞𝙘𝙨, 𝙞𝙢𝙖𝙜𝙞𝙣𝙜, 𝙖𝙣𝙙 𝘼𝙄 𝙞𝙣𝙩𝙤 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡𝙡𝙮 𝙧𝙚𝙡𝙞𝙖𝙗𝙡𝙚 𝙨𝙮𝙨𝙩𝙚𝙢𝙨 𝙞𝙨 𝙚𝙭𝙘𝙚𝙥𝙩𝙞𝙤𝙣𝙖𝙡… 𝙒𝙚 𝙗𝙚𝙡𝙞𝙚𝙫𝙚 𝙩𝙝𝙚𝙮 𝙖𝙧𝙚 𝙥𝙤𝙞𝙨𝙚𝙙 𝙩𝙤 𝙗𝙚𝙘𝙤𝙢𝙚 𝙖 𝙜𝙡𝙤𝙗𝙖𝙡 𝙡𝙚𝙖𝙙𝙚𝙧 𝙞𝙣 𝙩𝙞𝙨𝙨𝙪𝙚 𝙙𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘𝙨 𝙖𝙪𝙩𝙤𝙢𝙖𝙩𝙞𝙤𝙣, 𝙖𝙣𝙙 𝙬𝙚 𝙖𝙧𝙚 𝙚𝙭𝙘𝙞𝙩𝙚𝙙 𝙩𝙤 𝙨𝙪𝙥𝙥𝙤𝙧𝙩 𝙩𝙝𝙚𝙞𝙧 𝙟𝙤𝙪𝙧𝙣𝙚𝙮.” This funding will help Morphle scale manufacturing, expand globally, grow its engineering and research teams, and push forward its vision of Physical AI, the powerful convergence of intelligent software with high-fidelity hardware. We’re excited to partner with Rohit Hiwale, Ashish Manmode, Sunnel Daniel, and the brilliant Morphle Labs Inc. team as they redefine how the world approaches cancer diagnostics, faster, smarter, and with unmatched precision. Thank you, Bhuvana Kamath and The Economic Times, for spotlighting this important milestone. 📰✨ 📎 Read the full article here: https://lnkd.in/g2Wnm2Jr

🚀 𝗜𝗻𝗳𝗹𝗲𝘅𝗼𝗿 𝗩𝗲𝗻𝘁𝘂𝗿𝗲𝘀 𝘅 𝗠𝗼𝗿𝗽𝗵𝗹𝗲 𝗟𝗮𝗯𝘀 | 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 At Inflexor Ventures, we believe that some of the most transformative companies are built by founders who choose to solve the quiet, under-addressed problems, the ones hiding in plain sight, yet fundamental to global health and human outcomes. Our latest investment in Morphle Labs Inc., as they raise $𝟱𝗠 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔, is exactly that kind of story 🌍✨ For decades, histopathology, the core of cancer diagnostics, has remained one of the least automated parts of healthcare. While radiology and genomics have leapt ahead with digital adoption, labs worldwide still depend on manual, painstaking processes that slow down diagnosis, limit scale, and constrain specialists. Morphle is changing this, not with marginal improvements, but with a first-principles rebuild of how tissue diagnostics should work. Their flagship innovations- 🔹 𝗥𝗼𝗯𝗼𝗧𝗼𝗺𝗲®️, the world’s first high-throughput robotic microtome, and 🔹 𝗠𝗼𝗿𝗽𝗵𝗼𝗟𝗲𝗻𝘀, a next-gen AI-driven slide scanner — Together, create a fully automated pipeline that dramatically improves speed, consistency, and clinical readiness. With 80+ patents, a deeply technical founding team, and strong early traction across the U.S. and Europe, Morphle represents the kind of physical-AI innovation India is now capable of building for the world 🇮🇳➡️🌏 As our Partner Pratip Mazumdar shared during the announcement: “𝙈𝙤𝙧𝙥𝙝𝙡𝙚 𝙇𝙖𝙗𝙨 𝙞𝙨 𝙩𝙧𝙖𝙣𝙨𝙛𝙤𝙧𝙢𝙞𝙣𝙜 𝙤𝙣𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙢𝙤𝙨𝙩 𝙤𝙫𝙚𝙧𝙡𝙤𝙤𝙠𝙚𝙙 𝙮𝙚𝙩 𝙢𝙞𝙨𝙨𝙞𝙤𝙣-𝙘𝙧𝙞𝙩𝙞𝙘𝙖𝙡 𝙨𝙚𝙜𝙢𝙚𝙣𝙩𝙨 𝙤𝙛 𝙜𝙡𝙤𝙗𝙖𝙡 𝙝𝙚𝙖𝙡𝙩𝙝𝙘𝙖𝙧𝙚. 𝙏𝙝𝙚𝙞𝙧 𝙖𝙗𝙞𝙡𝙞𝙩𝙮 𝙩𝙤 𝙗𝙧𝙞𝙣𝙜 𝙩𝙤𝙜𝙚𝙩𝙝𝙚𝙧 𝙧𝙤𝙗𝙤𝙩𝙞𝙘𝙨, 𝙞𝙢𝙖𝙜𝙞𝙣𝙜, 𝙖𝙣𝙙 𝘼𝙄 𝙞𝙣𝙩𝙤 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡𝙡𝙮 𝙧𝙚𝙡𝙞𝙖𝙗𝙡𝙚 𝙨𝙮𝙨𝙩𝙚𝙢𝙨 𝙞𝙨 𝙚𝙭𝙘𝙚𝙥𝙩𝙞𝙤𝙣𝙖𝙡… 𝙒𝙚 𝙗𝙚𝙡𝙞𝙚𝙫𝙚 𝙩𝙝𝙚𝙮 𝙖𝙧𝙚 𝙥𝙤𝙞𝙨𝙚𝙙 𝙩𝙤 𝙗𝙚𝙘𝙤𝙢𝙚 𝙖 𝙜𝙡𝙤𝙗𝙖𝙡 𝙡𝙚𝙖𝙙𝙚𝙧 𝙞𝙣 𝙩𝙞𝙨𝙨𝙪𝙚 𝙙𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘𝙨 𝙖𝙪𝙩𝙤𝙢𝙖𝙩𝙞𝙤𝙣, 𝙖𝙣𝙙 𝙬𝙚 𝙖𝙧𝙚 𝙚𝙭𝙘𝙞𝙩𝙚𝙙 𝙩𝙤 𝙨𝙪𝙥𝙥𝙤𝙧𝙩 𝙩𝙝𝙚𝙞𝙧 𝙟𝙤𝙪𝙧𝙣𝙚𝙮.” This funding will help Morphle scale manufacturing, expand globally, grow its engineering and research teams, and push forward its vision of Physical AI, the powerful convergence of intelligent software with high-fidelity hardware. We’re excited to partner with Rohit Hiwale, Ashish Manmode, Sunnel Daniel, and the brilliant Morphle Labs Inc. team as they redefine how the world approaches cancer diagnostics, faster, smarter, and with unmatched precision. Thank you, Bhuvana Kamath and The Economic Times, for spotlighting this important milestone. 📰✨ 📎 Read the full article here: https://lnkd.in/g2Wnm2Jr

VC funds don’t get a big lump sum on Day 1. Instead, investors commit money, and the fund calls it only when there’s a deal to invest in or an expense to cover. That moment is a 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗖𝗮𝗹𝗹- the point where a promise becomes actual money. It keeps LPs flexible, helps VCs deploy at the right time, and makes sure cash isn’t sitting idle. Swipe through to get the basics of how capital calls keep the VC engine running. #VCVocab #CapitalCall #StartupFinance #VCExplained

Inflexor Ventures was recently featured in CNBC-TV18 Hindi’s coverage exploring how India’s next generation of wealth holders is increasingly directing capital toward the startup ecosystem. This shift is contributing to deeper investment in emerging technologies, and sustained value creation - momentum that is set to shape India’s innovation landscape in the decade ahead. Read the full story here: https://lnkd.in/gYQS_An5

Murali Krishna Gunturu, joined Smruthi Nadig of Analytics India Magazine(AIM) for an engaging conversation on how data, AI and deeptech are shaping the next wave of innovation in India. In the conversation, Murali dives into: • The imperatives for building globally competitive deep tech companies • ⁠What investors look for in tech-first founders • Key considerations around exits, regulation, and government policy • How broader market shifts are shaping India’s deep tech narrative For stakeholders across the innovation ecosystem, this episode offers an informed and comprehensive view of the opportunities and challenges ahead. Tune in and let us know your key takeaways! Watch the full episode here: https://lnkd.in/ggmh-Feb